Mizuho Reaffirms Underperform Rating for Valeant Pharmaceuticals International Inc.

Mizuho Reaffirms Underperform Rating for Valeant Pharmaceuticals International Inc.


's stock had its "underperform" rating restated by analysts at Mizuho in a note issued to investors on Thursday. They currently have a $11.00 price objective on the specialty pharmaceutical company's stock.



from Biotech News